Jan 092018
 
What Last Year's Top Stock Pickers Are Buying In 2018

At the start of each year for over three decades, the editorial team at MoneyShow.com surveys the nation’s leading newsletter advisors for their favorite stocks for the year ahead. We asked last year’s six top performers for an update on their 2017 picks and for their new favorite buys for 2018.

Dec 292017
 
MoneyShow's Top Stock Pickers of 2017

Top Stock Pickers of 2017: Biotechnology expert John McCamant deserves special recognition; his top pick from last year rose an astounding 519%. We’ve asked John, and all these other outstanding advisors, to share their updated opinions on these top performing stocks from last year’s Top Picks 2017 report.

Myovant: Drug Offers ‘Best-in-Class’ Potential

 Comments Off on Myovant: Drug Offers ‘Best-in-Class’ Potential
Nov 142017
 
Myovant: Drug Offers 'Best-in-Class' Potential

Myovant Sciences Ltd. (MYOV:NYSE) is an emerging biotech leader focused on developing and commercializing innovative therapies for women’s health and endocrine diseases.

Esperion: Grand Slam in Cholesterol Reduction

 Comments Off on Esperion: Grand Slam in Cholesterol Reduction
Sep 072017
 
Esperion: Grand Slam in Cholesterol Reduction

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.

Intrexon: Biotech, Biofuels & Fish Farming

 Comments Off on Intrexon: Biotech, Biofuels & Fish Farming
Jul 092017
 
Intrexon: Biotech, Biofuels & Fish Farming

Intrexon (XON) has had a very busy few weeks as the company has delivered a slew of positive news, explains John McCamant, editor of The Medical Technology Stock Letter.

Top Picks 2017: Madrigal

 Comments Off on Top Picks 2017: Madrigal
Jan 242017
 
Top Picks 2017: Madrigal

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.

Top Picks 2017: The Medicines Company

 Comments Off on Top Picks 2017: The Medicines Company
Jan 182017
 
Top Picks 2017: The Medicines Company

The next-generation of cholesterol drugs were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of the Medical Technology Stock Letter.

Top Picks 2017: Incyte (1-06-2017)

 Comments Off on Top Picks 2017: Incyte (1-06-2017)
Jan 072017
 
Top Picks 2017: Incyte (1-06-2017)

This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests John McCamant, editor The Medical Technology Stock Letter.

10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

 Comments Off on 10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)
Nov 292016
 
10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

November 17, 2016 Opinion : 10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16) The Republican sweep of Washington has generated a ton of enthusiasm for biotech stocks. They’re up 10% to 15% since the elections. As a result, biotech analysts’ phones are ringing off the hook again after a depressingly bleak […]

Incyte: A Promising Pipeline (11-14-2016)

 Comments Off on Incyte: A Promising Pipeline (11-14-2016)
Nov 162016
 
Incyte: A Promising Pipeline (11-14-2016)

John McCamant, editor The Medical Technology Stock Letter, reviews a favored biotech stock Incyte (INCY), noting that the company will have a very strong presence at the American Society of Hematology (ASH) Annual Meeting 2016 in early December.

Trump Victory Brings V-Shaped Reaction (11-9-16)

 Comments Off on Trump Victory Brings V-Shaped Reaction (11-9-16)
Nov 102016
 
Trump Victory Brings V-Shaped Reaction (11-9-16)

The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +8%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration.

Alkermes: Progress in Treating Depression (11-2-2016)

 Comments Off on Alkermes: Progress in Treating Depression (11-2-2016)
Nov 032016
 
Alkermes: Progress in Treating Depression (11-2-2016)

This recommended biotech stock (Alkermes) has delivered the goods with outstanding positive top line data in a treatment for depressions, explains leading biotech analyst John McCamant, editor of The Medical technology Stock Letter.

Catalysts in Biotech (8-19-2016)

 Comments Off on Catalysts in Biotech (8-19-2016)
Aug 222016
 
Catalysts in Biotech (8-19-2016)

John McCamant of BioInvest’s Medical Technology Stock Letter, updates us on the state of the sector, the primary catalysts he see over the rest of the year, and a trio of favorite stocks poised for potentially exciting results.